Study of Ruxolitinib in Pancreatic Cancer Patients (RECAP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01423604 |
Recruitment Status :
Completed
First Posted : August 26, 2011
Results First Posted : August 29, 2016
Last Update Posted : February 12, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Cancer | Drug: Capecitabine Drug: Ruxolitinib Drug: Placebo | Phase 2 |
The study consisted of an open-label, safety run-in period that was composed of 1 patient cohort with 9 patients/cohort. This phase of the study determined the safety of the capecitabine/ruxolitinib combination in this patient population.
A randomized, double-blind study with two treatment arms was conducted once the safety run-in results from the first part of the study showed that the capecitabine/ruxolitinib combination was safe and additional patients could be treated. All patients have received capecitabine therapy in addition to the ruxolitinib or placebo (Study Drug).
Treatment for all patients consisted of repeating 21-day cycles. Capecitabine was self-administered for the first 14 days of each cycle, and the Study Drug was self-administered during the entire 21-day cycle. Treatment cycles continued as long as the regimen was tolerated and the patient did not meet any of the discontinuation criteria. In the event of disease progression, capecitabine therapy was discontinued but the Study Drug could continue to be administered. Subjects who discontinued treatment with the Study Drug continued to be followed to obtain information regarding subsequent treatment regimens and survival.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 136 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial) |
Study Start Date : | July 2011 |
Actual Primary Completion Date : | June 2013 |
Actual Study Completion Date : | November 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Capecitabine and ruxolitinib |
Drug: Capecitabine
Capecitabine starting dose - 2000 mg/m^2 (1000 mg/m^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.) Drug: Ruxolitinib Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.) |
Placebo Comparator: Capecitabine and placebo |
Drug: Capecitabine
Capecitabine starting dose - 2000 mg/m^2 (1000 mg/m^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.) Drug: Placebo Placebo matching ruxolitinib |
- Overall Survival [ Time Frame: Primary analysis includes study data from the start of the study (first dose for that subject) until the death of the subject (up to 8 months). ]Overall survival was measured as the length of time (in days) between the randomization date and the date of death.
- Progression-Free Survival (PFS) [ Time Frame: Analysis includes study data from the start of the study (first dose for that subject) until death or PD, whichever was earlier up to 8 months. ]Progression-free survival was defined as the length of time between the date of randomization and the earlier of death or progressive disease (PD), whichever was earlier, as assessed by RECIST. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
- Objective Response Rate [ Time Frame: Measured every 4 weeks for duration of study treatment (up to 8 months) ]Objective response rate (ORR) was defined as the percentage of participants with either a confirmed complete response (CR) or partial response (PR) measured by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria during the treatment period. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- Durable Response Rate [ Time Frame: Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months) ]Durable response was defined as subjects with a response of Partial response (PR) or better at 2 subsequent measurements that were at least 4 weeks apart.
- Summary of Clinical Benefit [ Time Frame: Measured every 4 weeks until death or PD, whichever was earlier (up to 8 months) ]
A subject was considered a clinical benefit responder if he/she met at least 1 of the following criteria:
- Subject showed improvement in at least one of the following parameters on successive scheduled observations without worsening in the others: pain intensity, analgesic use, or performance status
- Subject was stable or improved on the pain intensity, analgesic use, and performance status and had a ≥ 7% increase in body weight maintained for 2 consecutive reporting periods that was not because of fluid accumulation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older
- Diagnosis of metastatic pancreatic cancer; subjects must have had measurable, or evaluable disease that was histologically confirmed
- Karnofsky performance status of ≥ 60
-
Subjects must have failed 1st-line gemcitabine treatment for metastatic pancreatic cancer:
o An alternate chemotherapeutic agent was an acceptable substitute as 1st-line therapy in the event that the subject was intolerant to or ineligible to receive gemcitabine
- ≥ 2 weeks elapsed from the completion of previous chemotherapy, and subjects must have recovered or been at new stable baseline from any related toxicities
Exclusion Criteria:
- More than 1 prior chemotherapy regimen (not including adjuvant therapy) for metastatic disease
- Evidence of central nervous system (CNS) metastases (unless stable for > 3 months) or history of uncontrolled seizures
- Ongoing radiation therapy or prior radiation therapy administered as a second-line treatment
- Other active malignancy except basal or squamous carcinoma of the skin
- Inability to swallow food or any condition of the upper GI tract that precluded administration of oral medications
- Inadequate renal, hepatic and bone marrow function demonstrated by clinical observations and/or laboratory assessments
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01423604
United States, Alabama | |
Birmingham, Alabama, United States | |
United States, Arkansas | |
Hot Springs, Arkansas, United States | |
United States, California | |
Burbank, California, United States | |
Los Angeles, California, United States | |
Santa Monica, California, United States | |
United States, Colorado | |
Denver, Colorado, United States | |
United States, Connecticut | |
Stamford, Connecticut, United States | |
United States, Florida | |
Boynton Beach, Florida, United States | |
Fort Myers, Florida, United States | |
Saint Petersburg, Florida, United States | |
United States, Illinois | |
Arlington Heights, Illinois, United States | |
Elks Grove Village, Illinois, United States | |
United States, Indiana | |
Indianapolis, Indiana, United States | |
United States, Iowa | |
Sioux City, Iowa, United States | |
United States, Kentucky | |
Lexington, Kentucky, United States | |
Louisville, Kentucky, United States | |
United States, Massachusetts | |
Worcester, Massachusetts, United States | |
United States, Michigan | |
Ann Arbor, Michigan, United States | |
Detroit, Michigan, United States | |
Grand Rapids, Michigan, United States | |
Novi, Michigan, United States | |
United States, Minnesota | |
Minneapolis, Minnesota, United States | |
United States, Missouri | |
Saint Louis, Missouri, United States | |
United States, New Jersey | |
Voorhees, New Jersey, United States | |
United States, New Mexico | |
Albuquerque, New Mexico, United States | |
United States, New York | |
Lake Success, New York, United States | |
United States, North Carolina | |
Durham, North Carolina, United States | |
Hickory, North Carolina, United States | |
United States, Ohio | |
Canton, Ohio, United States | |
Dayton, Ohio, United States | |
United States, Oklahoma | |
Tulsa, Oklahoma, United States | |
United States, Oregon | |
Bend, Oregon, United States | |
Portland, Oregon, United States | |
United States, Pennsylvania | |
Danville, Pennsylvania, United States | |
Pittsburgh, Pennsylvania, United States | |
United States, Tennessee | |
Knoxville, Tennessee, United States | |
United States, Texas | |
San Antonio, Texas, United States | |
United States, Virginia | |
Richmond, Virginia, United States | |
United States, Wisconsin | |
Green Bay, Wisconsin, United States |
Study Director: | William Williams, MD | Incyte Corporation |
Responsible Party: | Incyte Corporation |
ClinicalTrials.gov Identifier: | NCT01423604 |
Other Study ID Numbers: |
18424-262 |
First Posted: | August 26, 2011 Key Record Dates |
Results First Posted: | August 29, 2016 |
Last Update Posted: | February 12, 2018 |
Last Verified: | January 2018 |
Metastatic pancreatic cancer |
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases |
Endocrine System Diseases Capecitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |